Canakinumab, an interleukin (IL) 1 blocker, can now be prescribed to treat patients with active Still’s disease and adult-onset Still’s disease (AOSD)…

Canakinumab, an interleukin (IL) 1 blocker, can now be prescribed to treat patients with active Still’s disease and adult-onset Still’s disease (AOSD)…
The recommendations for MIS-C focus on general guidance, diagnostic evaluation and therapy options, as well as comparing and contrasting the features of MIS-C and Kawasaki disease.
Marilynn Larkin |
NEW YORK (Reuters Health)—COVID-19-infected patients with rheumatic disease were more likely to experience respiratory failure than those without rheumatic disease, according to a retrospective study in China. “Immune dysregulation underlying rheumatic diseases may affect the disease manifestation of COVID-19,” Dr. Jixin Zhong of Huazhong University of Science and Technology, Wuhan, tells Reuters Health by email….
Renée Bacher |
Japanese pediatrician Tomisaku Kawasaki, MD, who identified an inflammatory syndrome that affects children, died on June 5 in Tokyo. He was 95. Tenacity & Attention to Detail Born Feb. 7, 1925, in Tokyo, Dr. Kawasaki graduated from medical school at what is now Chiba University in Chiba, Japan, in 1948 and worked as staff pediatrician…
Will Boggs, MD |
NEW YORK (Reuters Health)—Two new reports in JAMA strengthen the link between SARS-CoV-2 infection and pediatric inflammatory multisystem syndrome (PIMS). Pediatricians from several communities have reported children who developed fever and multisystem inflammation during the COVID-19 pandemic. Some children were critically ill and some had characteristics similar to Kawasaki disease or Kawasaki disease shock syndrome….
Daniel F. Battafarano, DO, MACP, FACR |
My first-ever medical mission trip, after 37 years of medical practice, was to Teleman, Alta Verapaz, Guatemala. Prior to the trip, my excitement as an adult-trained rheumatologist was balanced against my apprehension about witnessing new diseases, caring for children and practicing in an austere environment with limited medical resources. As directed by the travel clinic,…
Srujana Pachigolla, MD, & Adegbenga Bankole, MD |
Primary hemophagocytic lymphohistiocytosis (HLH) is caused by genetic mutations and inherited syndromes; it therefore occurs in the pediatric age group. Secondary HLH, however, is more common in adults and is often triggered by other disease states, such as malignancies, chronic immunosuppression, infections and autoimmune disease.1,2 Macrophage activation syndrome (MAS) is a subset of secondary HLH…
Mark Gorelik, MD |
A pediatric rheumatologist in the thick of treating children with COVID-19 confronts a new and evolving syndrome.
Reuters Staff |
NEW YORK (Reuters Health)—Cases of a rare hyperinflammatory syndrome believed to be linked to novel coronavirus continue to be reported around the world. During a 10-day period in mid-April, clinicians in London treated an “unprecedented” cluster of eight children with hyperinflammatory shock, who presented to Evelina London Children’s Hospital pediatric intensive care unit (ICU), triggering…
Julie Steenhuysen |
CHICAGO (Reuters)—On May 13, U.S. health officials said they will issue an alert telling doctors to report cases of a rare life-threatening inflammatory syndrome associated with COVID-19 in children to their state and local health departments. The alert from the U.S. Centers for Disease Control and Prevention (CDC) will be released on Wednesday or Thursday,…